e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Drug delivery and pharmacokinetics I
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Optimization of inhalation treatment – Assessment of the influence of diluent and air humidity on particle distribution of colistin administered by BCTS method [bronchial control treatment system]
Z. Podolec, J. Siekaniec (Cracow, Poland)
Source:
Annual Congress 2010 - Drug delivery and pharmacokinetics I
Session:
Drug delivery and pharmacokinetics I
Session type:
E-Communication Session
Number:
2028
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Z. Podolec, J. Siekaniec (Cracow, Poland). Optimization of inhalation treatment – Assessment of the influence of diluent and air humidity on particle distribution of colistin administered by BCTS method [bronchial control treatment system]. Eur Respir J 2010; 36: Suppl. 54, 2028
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Optimization of inhalation treatment – Evaluation of influence of spacer integrated with the spirometer on aerosol particle distribution from pMDI-EB
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Optimization of inhalation treatment – Evaluation of influence of PNEUMOlogic® and Optimiser® spacers on aerosol particle distribution from pMDI-EB
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Effective and efficient nebulization of alpha
1
-proteinase inhibitor (alpha
1
-PI) for inhalation therapy using the AKITA
2
® APIXNEBÔ nebulizer system
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV)
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV)
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
Effects on the respirable dose < 3.3 µm of an isotonic DSCG inhalation solution (IsoCROM) comparing different nebuliser systems mimicking 3 year old childrens' breathing patterns
Source: Eur Respir J 2007; 30: Suppl. 51, 460s
Year: 2007
Effect of 3 different nebulisers on the aerosol delivery performance of isotonic disodium comoglycate (IsoCROM)
Source: Eur Respir J 2006; 28: Suppl. 50, 212s
Year: 2006
Study of the use of Chartis® pulmonary assessment system to optimize subject selection for endobronchial lung volume reduction (ELVR) – Results and subgroup analysis
Source: Annual Congress 2011 - Endoscopic lung volume reduction: hype or hope?
Year: 2011
Comparative
in vitro
performance of a new re-usable breath-actuated nebulizer (BAN) with other high performance systems intended for domiciliary use – 2: Portable battery-compressor
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012
Comparative
in vitro
performance of a new re-usable breath-actuated nebulizer (BAN) with other high performance systems intended for domiciliary use – 1: Table-top compressors
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
Delivery of medication by breath-actuated nebulizer (BAN) is similar when used with differing inhalation / exhalation ratios: A contrast to breath enhanced nebulizer (BEN) behavior
Source: International Congress 2014 – Respiratory symptoms in primary care populations
Year: 2014
LATE-BREAKING ABSTRACT: Effect of inhalation profiles and throat geometries on predicted lung deposition of budesonide and formoterol (BF) when inhaled through two different devices
Source: International Congress 2014 – Innovative technology and techniques in respiratory function
Year: 2014
Effect of nebuliser position on aerosol performance during high flow nasal therapy
Source: International Congress 2018 – New tools for managing respiratory failure
Year: 2018
Comparison between SCOT-15® and Perfadex® as lung preservation solutions
Source: Annual Congress 2011 - Immunobiology in the transplanted lung: experimental and clinical evaluations
Year: 2011
In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles
Source: International Congress 2015 – Lung function: waiting to exhale...
Year: 2015
Valved holding chambers (VHCs) can have different medication delivery performance as a function of delay interval following actuation of the pressurized metered dose inhaler (pMDI)
Source: International Congress 2014 – Respiratory symptoms in primary care populations
Year: 2014
Tolerance of nebulised gentamicin in adult bronchiectasis – A single centre study
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Sensitivity and specificity of airway hyperreactivity (AHR) based on methacholine challenge (MCH) tests – Comparison of sG
eff
with FEV
1
and MEF
50
as target parameter
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012
Effect of I:E ratio on the respirable delivered dose from nebulizers
Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine
Year: 2020
Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and
Pseudomonas aeruginosa
infection
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept